Life WhispererLife WhispererLife WhispererLife Whisperer
  • Home
  • Products
    • Life Whisperer Genetics
    • Life Whisperer Viability
    • Life Whisperer Genetics
    • Life Whisperer Oocytes
    • Life Whisperer Endometrial Receptivity
  • Distribution
  • News & Science
    • Press
    • IVF-X
    • Publications
  • About
  • Request a Trial
  • Home
  • Products
    • Life Whisperer Embryo Quality
    • Life Whisperer Viability
    • Life Whisperer Genetics
    • Life Whisperer Oocytes
    • Life Whisperer Endometrial Receptivity
  • Distribution
  • News & Science
    • Press
    • IVF-X
    • Publications
  • About
  • Request a Trial
  • Home
  • Products
    • Life Whisperer Genetics
    • Life Whisperer Viability
    • Life Whisperer Genetics
    • Life Whisperer Oocytes
    • Life Whisperer Endometrial Receptivity
  • Distribution
  • News & Science
    • Press
    • IVF-X
    • Publications
  • About
  • Request a Trial

Life Whisperer secures TechInSA funding to accelerate commercial growth of its embryo selection technology for IVF

IVF Embryo Selection
IVF Embryo Selection

Life Whisperer, an AI startup in the fertility sector, has secured its first round of funding through the SA Early Commercialization Fund initiative administered by TechInSA. The fund is designed to support the commercialization of innovative technologies that have global market potential. 

The funding will support secondary validation of Life Whisperer’s approach, which applies AI-driven image analysis such as machine learning, as well as morphological assessment of embryos to assist in the selection of healthy embryos for IVF implantation.

Dr Michelle Perugini says “the South Australian government recognizes the value of providing support to companies with innovative ideas, and we hope to give back by building a world-leading capability for clinical decision support”.

Life Whisperer will use the funding to assist in the development of a scalable cloud-based software product that provides image analysis for embryo selection to clinics who perform IVF globally.

The value of Life Whisperer is that it is a completely non-invasive approach to analyzing embryos. Dr Jonathan Hall says “our approach does not require significant process change, does not tamper with the embryos, and does not require specialized hardware. This will hopefully reduce the barriers to use by clinics for this type of approach, and will see patients benefiting from the technology sooner.”

Life Whisperer plans to work with commercial partners to complete the next phase of validation.

For more information email Info@LifeWhisperer.co or Dr Michelle Perugini on +61 412 396 960.

Connect with us
Share
68

Related posts

September 4, 2023

Life Whisperer AI featured in three oral presentations at the Asia Pacific fertility conference, ASPIRE 2023


Read more
August 22, 2023

Presagen sponsors Women’s Health Innovation Summit (WHIS) USA to support the future health of woman-kind


Read more
August 8, 2023

Independent study shows Life Whisperer’s AI can predict the viability of embryos that have previously been frozen


Read more
July 28, 2023

Presagen’s CEO Dr Michelle Perugini featured on SBS Insights TV program discussing benefits, risks and applications of AI technology


Read more

Comments are closed.

HIPAA and GDPR compliant and ISO 13485 certified.

CE Logo

Life Whisperer Viability and Genetics are commercially available in Australia, Canada, Europe (EEA), UK, Japan, India, UAE, Hong Kong, Israel, Malaysia, Thailand, Vietnam, Singapore, New Zealand, Turkey, Trinidad & Tobago, and Guyana (not available in the USA).

Life Whisperer Genetics is commercially available in the USA.

For sale to healthcare professionals only.

© Life Whisperer Diagnostics Pty Ltd     Terms and conditions   |   Privacy Policy   |   Fair Use Policy
  • Home
  • Products
  • Distribution
  • News & Science
  • About
  • Request a Trial